Transdermal Central Nervous System Drug Therapeutics CNS

Unlike several other disease segments, progress toward curative medicine for neurological and related central nervous system disorders has remained elusive. The result is a therapeutic segment that relies heavily on control of symptoms and palliative care. This disappointing picture is being exacerbated by disease trends that are increasing the morbidity and mortality associated with CNS ailments in the general population. These trends include the growing incidence of neurological disorders associated with longevity and aging, and significant increases in the number of children diagnosed with autism. Because diseases of the central nervous system often result in compromised cognitive and/or motor skills that can increase the level of involuntary non-compliance with therapeutic protocols, transdermal delivery of drugs targeting CNS disorders is generally viewed as a method that can increase patient safety and improve outcomes. In addition to the handful of FDA-approved transdermal CNS products, more than a dozen companies are currently pursuing a range of APIs in transdermal delivery systems that target neurological and CNS conditions.

Publication Date: January 2010

Summary of Contents (see Prospectus for full Contents)

Executive Summary

Scope and Definitions

The Current CNS Therapy Market

Unmet Needs in CNS Disease Treatment

The Opportunity for Transdermal Delivery of CNS Therapeutics

The CNS Therapeutics Market Opportunity

Changes and Trends in Incidence and Morbidity

The Demand Picture for CNS Therapeutics

Competitive Landscape

Factors Limiting Growth

Transdermal Drug Delivery to the CNS

Patch Designs and Construction

Transdermal Patch Manufacturing and Packaging

The Patch Manufacturing Ecosystem

CNS Patch Economics

Passive vs Active Delivery Systems

Transdermal Gels

The Global Market for Transdermal CNS Therapeutics –Disease Segment Analysis

ADHD

Alzheimer’s Disease

Dementia

Depression

Migraine

Nausea

Parkinson’s Disease

Restless Leg Syndrome

Schizophrenia

Transdermal CNS Drug Product Analysis and Market Assessments

FDA Approved Transdermal CNS Prescription Products

MAO Inhibitors

Cholinergic Agents

Dopamine Agonists

CNS Stimulants

5-HT3 Receptor Antagonists

Commercialized Transdermal CNS Products (Non-FDA Approved)

Non-U.S. Regional Product Assessment & Market Impact

Strategic Factors and Branding Issues

Development-Stage Transdermal CNS Prescription Products

AChE Inhibitors

Cholinergic Agents

Dopamine Agonists

5-HT3 Receptor Antagonists

Serotonin Agonists

Other Drug Classes

Transdermal CNS Therapeutics Market Factors

Regulations and Approvals

Clinical Trials

Indications Prescribing Guidelines and Off-Label Prescribing

Rx-to-OTC Switching

Skin Patch Revenue Models

Market Participant Profiles

About Our Reports

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.